Multiple sclerosis registries in Europe – An updated mapping surveyAnna Glaser, Christoph Thalheim, Alessandro Giacomoni et al.|Multiple Sclerosis and Related Disorders|2018Cited by 67
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12
Big Multiple Sclerosis Data network: an international registry research networkAnna Glaser, Jan Hillert, Helmut Butzkueven et al.|Journal of Neurology|2024Cited by 12
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Sifat Sharmin et al.|BMC Medical Research Methodology|2022Cited by 6